These results validate Celecoxib’s role as a multi-target therapeutic agent, prioritizing PDK1 as a focal point for further drug development and clinical investigation in AD and ALS, while also supporting its potential in PD through CASP9 modulation. This evidence concerns the gene CASP9 and amyotrophic lateral sclerosis.